文献速递神经免疫

多发性硬化的B细胞治疗:进入新时代

B-cell Therapy for Multiple Sclerosis: Entering an era.
PubMed 文献 · Ann Neurol · 2018-01-01

本文综述靶向CD20阳性B细胞的单克隆抗体在多发性硬化中的治疗作用。B细胞清除疗法对复发型MS高度有效,且是首个被证明能延缓原发进展型MS残疾恶化的方法。文章还讨论了B细胞在MS自身免疫中的角色、奥瑞珠单抗等抗CD20疗法的临床数据、安全性及处方考虑。

要点

  • 抗CD20 B细胞清除疗法对复发型MS高度有效。
  • 该疗法是首个被证明能延缓原发进展型MS残疾恶化的治疗。
  • 需关注抗CD20疗法的安全性及处方实践问题。

核心结论

  • 靶向CD20阳性B细胞疗法是MS重要的新治疗选择,对复发型高度有效且首次证明可延缓原发进展型MS残疾恶化。

研究设计与样本

  • 综述,检索范围未在摘要中报告。

主要发现

  • B细胞清除疗法对复发型MS高度有效。
  • B细胞清除疗法是首个被证明能延缓原发进展型MS残疾恶化的治疗方法。
  • 临床经验积累和对体液免疫认识的深入促进了MS免疫发病机制的解码。

临床怎么用

  • 奥瑞珠单抗及其他抗CD20疗法可用于治疗MS,需考虑安全性和处方实践。

局限性

  • 抗CD20疗法在MS中的恰当作用、局限性及未来基于B细胞的治疗前景仍有未解问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Monoclonal antibodies that target CD20 expressing B cells represent an important new treatment option for patients with multiple sclerosis (MS). B-cell-depleting therapy is highly effective against relapsing forms of the disease and is also the first treatment approach proven to protect against disability worsening in primary progressive MS. Moreover, evolving clinical experience with B-cell therapy, combined with a more sophisticated understanding of humoral immunity in preclinical models and in patients with MS, has led to major progress in deciphering the immune pathogenesis of MS. Here, we review the nuanced roles of B cells in MS autoimmunity, the clinical data supporting use of ocrelizumab and other anti-CD20 therapies in the treatment of MS, as well as safety and practical considerations for prescribing. Last, we summarize remaining unanswered questions regarding the proper role of anti-CD20 therapy in MS, its limitations, and the future landscape of B-cell-based approaches to treatment. Ann Neurol 2018;83:13-26.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Greenfield AL, Hauser SL. B-cell Therapy for Multiple Sclerosis: Entering an era. Ann Neurol. 2018. PMID: 29244240. doi:10.1002/ana.25119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。